atosiban / Generic mfg. - LARVOL DELTA

The biased OTR ligands -atosiban and carbetocin- differentially inhibit early or late formalin-induced nociception in rats. (PubMed, Neuropharmacology) - "Late hypersensitivity correlated with increased levels of phosphorylated S6 protein in the spinal tissue, an effect partly blocked by atosiban. These data suggest that carbetocin prevents early nociception in males via OTR-Gq, and atosiban blocks late hypersensitivity in both sexes via OTR-Gi/o, implying that OTR-biased activation underlies the sexual dimorphism observed in oxytocin-induced antinociception."

Journal • Preclinical • Immunology • Infectious Disease • Inflammation • Pain • Respiratory Diseases

Inhibition of TRPM3 by Primidone Provides a Potential Therapeutic Method for Adenomyosis Management. (PubMed, Drug Des Devel Ther) - "To test the expression profile of transient receptor potential channels (TRPs) in adenomyosis patients and evaluate the effects of primidone on tamoxifen-induced adenomyosis mice...From 10 weeks after birth, primidone (2 mg/kg/d) and atosiban (1 mg/kg/d) were given separately to adenomyotic mice by intraperitoneal injection for 3 weeks...Forty-seven DEGSSs were identifieSd after primidone treatment, and bioinformatics analysis predicted that they were enriched in the cell cycle and cell division. The expression profile of TRP channels varies significantly in adenomyosis patients, and primidone may provide a potential therapeutic method for adenomyosis management."

Journal • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health • TRPA1 • TRPM3 • TRPV1

Atosiban and managing women in preterm labour. (PubMed, Lancet) - No abstract available

Journal

Atosiban versus placebo for threatened preterm birth (APOSTEL 8): a multicentre, randomised controlled trial. (PubMed, Lancet) - P4 | "We did not demonstrate superiority of atosiban over placebo in improving neonatal outcomes as treatment for threatened preterm birth from 30+0 to 33+6 weeks of gestation. As the primary goal of tocolysis should be improvement of neonatal outcomes, our outcomes question the standardised use of atosiban as treatment for threatened preterm birth from 30+0 to 33+6 weeks of gestation. Our findings should reduce practice variation across countries and will contribute to evidence-based treatment for patients with threatened preterm birth."

Journal

Atosiban in individuals with previous implantation failure undergoing frozen blastocyst transfer: a randomized controlled trial. (PubMed, Hum Reprod) - P4 | "Our study shows do not support the routine use of intravenous Atosiban to improve pregnancy outcomes among individuals undergoing frozen embryo transfers."

Clinical • Journal • Genetic Disorders

In-silico Approach to Combat Methicillin-resistant Staphylococcus aureus: Targeting RelP Protein with Inhibitor Peptide to Mitigate Drug Resistance. (PubMed, Curr Drug Discov Technol) - "Peptide therapeutics is a novel approach researchers are presently exploring as it pro-vides prompt significant results and promotes a new insight towards dealing with conditions like MDR. Pantocin wh-1 is a peptide drug currently listed as an accessible anti-tuberculosis peptide, and this study suggests the repurposing of this drug as a viable treatment option for MRSA infections."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

ROLE OF ATRIAL NATRIURETIC PEPTIDE AND OXYTOCIN IN GASTRIC EMPTYING DELAY INDUCED BY RIGHT ATRIAL STRETCH IN RATS. (PubMed, Am J Physiol Regul Integr Comp Physiol) - "One week later, rats were randomly subjected for pretreatment with NaCl 0.15 M (control), atosiban (AT, OT-antagonist), anantin (ANT, ANP-antagonist), or dexamethasone (DEX). In turn, oxytocin treatment decreased GE and increased plasma ANP, OT and CORT levels, while AT, ANT and DEX prevented OT-induced GE delay. Hence, AS delayed GE of liquid in rats, a phenomenon that involves oxytocinergic pathways and ANP activity."

Journal • Preclinical • Cardiovascular • Gastrointestinal Disorder

Combination of rTMS and oxytocin agonist attenuate depression-like behavior after postpartum depression in mice. (PubMed, Brain Res) - "Oxytocin acetate (agonist) and atosiban (antagonist) were administered by injection twice daily for three consecutive days following the model according to the established protocol...Nonetheless, OTA therapy followed by rTMS did not exhibit the same pattern of outcomes. Our findings indicate that the combination of rTMS stimulation and an oxytocin agonist in a PPD model may mitigate depression-like behavior."

Journal • Preclinical • CNS Disorders • Depression • Insomnia • Major Depressive Disorder • Mental Retardation • Mood Disorders • Postpartum Depression • Psychiatry • Sleep Disorder • DLG4 • SYP

De novo design of ribosomally synthesized and post-translationally modified peptides. (PubMed, Nat Chem) - "Using a pipeline to evaluate more than 1,000 peptides, the model was parameterized under uniform conditions in Escherichia coli for enzymes from different classes (graspetide, spliceotide, pantocin, cyanobactin, glycocin, lasso peptide and lanthipeptide)...Empirically, RiPPs with the desired modifications constituted 7-67% of the total peptides produced, and 6 of our 8 peptide designs were successfully modified. This work is an example of the design of enzyme-modified peptides and libraries, using a framework that can be expanded to include new enzymes and chemical moieties."

Journal

Integrating Bulk RNA and Single-Cell RNA Sequencing Identifies and Validates Lactylation-Related Signatures for Intervertebral Disc Degeneration. (PubMed, J Cell Mol Med) - "In conclusion, the lactylation correlates positively with IVDD and the LRG signature could be used as a biomarker for the effective clinical treatment of IVDD. CBX3 emerged as one of the key LRGs in IVDD, and atosiban acetate, as a specific inhibitor for CBX3, may be a promising therapeutic candidate for IVDD by affecting lactylation."

Biomarker • Journal • CBX3

Intranasal oxytocin alleviates postsurgical pain and comorbid anxiety in mice: Participation of BK(Ca) channels in the hippocampus. (PubMed, Neuropharmacology) - "Intranasal OXT significantly ameliorated this postsurgical pain and associated anxiety in a dose-dependent manner, while Intra-CA3 microinjection of OTR antagonist atosiban or the BK(Ca) channel blocker paxilline reduced the effect of OXT in incisional mice...Conversely, intra-CA3 microinjection of BK(Ca) channel blocker paxilline in normal mice was sufficient to evoke mechanical pain hypersensitivity. Taken together, our data suggested that intranasal OXT administration exerted analgesic and anxiolytic effects in incisional mice by opening BK(Ca) channels in the CA3 subregion of hippocampus."

Journal • Preclinical • Immunology • Mood Disorders • Pain • Psychiatry • CA3

Oxytocin Protects Against Corticosterone-Induced DA Dysfunction: An Involvement of the PKA/CREB Pathway. (PubMed, Neurochem Res) - "In addition, the neuroprotective effect of OXT was abolished by atosiban (an OXT receptor antagonist) or H89 (a PKA inhibitor). Our results suggest that OXT protects dopaminergic neuroblastoma cells from CORT-induced DA dysfunction, potentially through the involvement of oxytocin receptors and the PKA/CREB signaling pathway. These findings contribute to the understanding of the neurobiological mechanisms underlying stress resilience and highlight potential pathways for developing targeted treatments that leverage the neuroprotective properties of OXT to address disorders characterized by DA dysregulation and impaired stress responses."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • CNS Disorders • CNS Tumor • Depression • Genetic Disorders • Mental Retardation • Mood Disorders • Neuroblastoma • Oncology • Psychiatry • Schizophrenia • Solid Tumor • Substance Abuse

Tocolysis and Neurodevelopment of Children Born Very Preterm. (PubMed, JAMA Netw Open) - "From modified Poisson regression with propensity score matching, the risk of overall neurodevelopmental disabilities (mild, moderate, or severe) at 5.5 years did not differ between preterm children exposed and not exposed to tocolytics (relative risk [RR], 1.11; 95% CI, 0.85-1.45; P = .44) or in preterm infants exposed to atosiban compared with those exposed to CCBs (RR, 0.94; 95% CI, 0.67-1.32; P = .71). In this study, tocolytics were not associated with neurodevelopmental disabilities among very preterm children surviving at 5.5 years."

Journal • Cerebral Palsy • CNS Disorders • Developmental Disorders • Psychiatry

Drug-induced hyponatraemia and possible related signals: Analysis of 659 cases reported to the Spanish Pharmacovigilance System and disproportionality analysis. (PubMed, Med Clin (Barc)) - "There are increasing reports of drug-induced hyponatraemia. It can be serious and seems to most often affect women over 65 years of age who take more than 1 medication. The time to onset varies and can be very long, so patient monitoring should be continuous throughout treatment. Hydrochlorothiazide is the drug with the highest number of reported cases in our setting. In terms of disproportionate reporting, diuretics leads the list, followed by antiepileptics as oxcarbazepine and eslicarbazepine. Safety signals were found for several drugs, more plausibly for pregabalin and paliperidone, thus a possible association between these drugs and hyponatraemia/SIAD is identified. This signal must be further studied. Meanwhile healthcare professionals should pay attention to this possibility. The reporting of suspected ADRs is essential to understand the risks associated with medicines once they are on the market."

Adverse events • Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Effects of nationwide adjustment of tocolysis protocol in the Netherlands on neonatal outcomes in women with threatened preterm birth and delivery at 30-32 weeks of gestation: A cohort study. (PubMed, Eur J Obstet Gynecol Reprod Biol X) - "Tocolytic therapy consisted of either nifedipine or atosiban. There was no significant difference in composite neonatal outcome in pregnancies resulting in spontaneous PTB between 30 and 32 weeks of gestation in 2018 (with tocolysis) compared to 2020 (no tocolysis). These results support the protocol adjustment to withhold tocolytic treatment in women with threatened PTB above 30 weeks of gestation."

Journal • Gastrointestinal Disorder • Hematological Disorders • Retinal Disorders • Retinopathy of Prematurity

The expanding antimicrobial diversity of the genus Pantoea. (PubMed, Microbiol Res) - "This review will explore the known antimicrobials produced by Pantoea: agglomerins, andrimid, D-alanylgriseoluteic acid, dapdiamide, herbicolins, pantocins, and the various Pantoea Natural Products (PNPs). It will include information on the structure of each compound, their genetic basis, biosynthesis, mechanism of action, spectrum of activity, and distribution, highlighting the significance of Pantoea antimicrobials as potential therapeutics and for applications in biocontrol."

Journal • Review

Investigation of effect peripheral kisspeptin treatment on hypothalamo-pituitary-gonadal axis and hypothalamo-pituitary-adrenal axis in male rats. (PubMed, Biol Futur) - "Adult male Wistar rats were randomly divided into seven groups as sham (control), kisspeptin (10 nmol), p234 (10 nmol), kisspeptin + p234, kisspeptin + antalarmin (10 mg/kg), kisspeptin + astressin2b (100 μg/kg), and kisspeptin + atosiban (0.250 mg/kg) (n = 10 each group)...Moreover, no significant difference was found in the concentration of pituitary oxytocin. Our results suggest that peripheral kisspeptin injection induces an activation in the HPG axis, but not in the HPA axis in male rats."

Journal • Preclinical

Impacts of Tocolytics on Maternal and Neonatal Glucose Levels in Women With Gestational Diabetes Mellitus. (PubMed, J Korean Med Sci) - "There is an increased risk of maternal hyperglycemia and neonatal hypoglycemia in women with GDM using atosiban and ritodrine tocolytics for preterm labor compared to those using nifedipine."

Journal • Retrospective data • Diabetes • Gestational Diabetes • Hypoglycemia • Metabolic Disorders

Distribution and comparative genomic analysis of antimicrobial gene clusters found in Pantoea. (PubMed, Front Microbiol) - "We evaluated the evolutionary history of these gene clusters relative to a cpn60-based species tree, considering the flanking regions of each cluster, %GC, and presence of mobile genetic elements, and identified potential occurrences of horizontal gene transfer. Lastly, we also describe the biosynthetic gene cluster of pantocin B in the strain Pantoea agglomerans Eh318 more than 20 years after this antibiotic was first described."

Journal • Gene Therapies

Comparison of Intratympanic Oxytocin and Dexamethasone in Cisplatin Ototoxicity: An Experimental Study. (PubMed, Indian J Otolaryngol Head Neck Surg) - "We also compared intratympanic atosiban (oxytocin antagonist) and oxytocin in cisplatin ototoxicity. There was no significant decrease in the frequencies of 2832 and 4004 after treatment in the oxytocin and dexamethasone group compared to pre-treatment in Distortion Product Otoacoustic Emission. As a result, it has been shown that intratympanic oxytocin may be an option that can be used in the treatment, although it is not as effective as dexamethasone in preventing cisplatin ototoxicity."

Journal • Oncology

Perioperative Use of Atosiban for Ultrasound-indicated Cerclage to Reduce Spontaneous Preterm Birth(sPTB) (clinicaltrials.gov) - P=N/A | N=334 | Completed | Sponsor: Children's Hospital of Chongqing Medical University

New trial

APOSTEL 8: Atosiban Versus Placebo in the Treatment of Late Threatened Pre-term Birth (clinicaltrials.gov) - P4 | N=760 | Completed | Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Recruiting ➔ Completed | Trial completion date: Jul 2024 ➔ Feb 2024 | Trial primary completion date: Jul 2023 ➔ Feb 2024

Trial completion • Trial completion date • Trial primary completion date

Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: study protocol of the 4-year APOSTEL 8 follow-up. (PubMed, BMJ Open) - P4 | "Results will be published in a peer-reviewed journal and shared with stakeholders and participants. This protocol is published before analysis of the results."

Clinical protocol • Journal • Obstetrics

Improvement of early miscarriage rates in women with adenomyosis via oxytocin receptor antagonist during frozen embryo transfer-a propensity score-matched study. (PubMed, Reprod Biol Endocrinol) - "Administering an oxytocin receptor antagonist during FET may reduce the early miscarriage rates in women with adenomyosis."

Journal • Retrospective data • Endometriosis • Gynecology • Infertility • Sexual Disorders • Women's Health

Perioperative Use of Atosiban for Ultrasound-indicated Cerclage to Reduce Spontaneous Preterm Birth(sPTB) (clinicaltrials.gov) - P=N/A | N=0 | Withdrawn | Sponsor: First Affiliated Hospital of Chongqing Medical University | N=334 ➔ 0 | Completed ➔ Withdrawn

Enrollment change • Trial withdrawal